EU expands approval of Alexion’s Soliris
admin 28th August 2019 Uncategorised 0At 48 weeks, 98% of patients treated with the drug were relapse free compared to 63% of patients receiving placebo.
More: EU expands approval of Alexion’s Soliris
Source: News